Industry news

Building great biopharma partnerships from A to D

Cormac Sheridan / BioWorld

Alignment and differentiation emerged as the two key requirements for successful partnerships during a panel discussion on the transformational deals that shaped the biopharma industry during 2016, here at BIO-Europe on Tuesday.

Biopharma deal-making holds up during investor exodus, price disputes

Cormac Sheridan / BioWorld

There are few countries to rival Germany for supplying gloomy gray weather in November. It's always a danger to rely too heavily on pathetic fallacy to describe the state of the biopharma industry, but to delegates arriving at the Koeln Messe Congress Centre for the 22nd annual BIO-Europe Fall meeting, the heavy clouds hanging over the cold waters of the Rhine seemed an apt metaphor for its current prospects.

10 November 2016

Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the third quarter ended September 30, 2016. In addition, the Company provided a pipeline update as well as a review of upcoming milestones. As of September 30, 2016, Syndax had $115.6 million in cash, cash equivalents and short-term investments.

10 November 2016

Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results

Neothetics, Inc.  (NASDAQ:NEOT) today provided a business update on its strategic initiatives and reported financial results for the third quarter 2016.

Biopharma stocks jump as Americans vote for Trump

Ben Adams / Fierce Biotech

An audible sigh of relief was heard this morning that, at last, the U.S. 2016 election is over. In the end, in what was an oft-controversial, hot-tempered and at times bewildering contest between two bitter rivals--and in what 18 months ago seemed impossible--Republican Donald Trump has become the president-elect of the United States.

Trust issues: Millennials are more skeptical of pharma than older generations

Beth Snyder Bulik / FiercePharmaMarketing

Millennials on both sides of the healthcare coin are skeptical of pharma companies. Both younger patients and doctors don’t trust Big Pharma, according to doctor social network Sermo. And it may be the drug companies’ fault.

Research on new, rapid screening test identifies potential therapies against drug-resistant bacteria

U.S. National Institute of Health

Researchers at the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), Clinical Center and National Institute of Allergy and Infectious Diseases (NIAID) have created a new way to identify drugs and drug combinations that may potentially be useful in combating infections that are resistant to many different antibiotics. They developed an assay (test) to rapidly screen thousands of drugs to determine how effective they were against a variety of types of resistant bacteria.

09 November 2016

Clearside Biomedical, Inc. Announces Third Quarter 2016 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter ended  September 30, 2016  and provided an update on its development programs.

09 November 2016

Miramar Labs, Inc. ® Reports Record Third Quarter 2016 Financial Results

Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today financial results for the third quarter ended September 30, 2016.

Stanford readies for CRISPR human testing after sickle cell success

Ben Adams / Fierce Biotech

Scientists from Stanford University School of Medicine have used CRISPR in early-stage work to patch up the gene that causes sickle cell disease as they eye human trials in 2018.